2023 World Conference on Lung Cancer (Posters)-P1.27. NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma

P1.27. NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the safety and efficacy of neoadjuvant icotinib plus chemotherapy in patients with resectable, stage II-IIIB EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).<br /><br />The study included 30 patients who received neoadjuvant therapy consisting of icotinib for 8 weeks and concurrent chemotherapy for 2 cycles, followed by surgical resection. The median follow-up was 12.4 months.<br /><br />The results showed that neoadjuvant icotinib plus chemotherapy was well-tolerated, with no treatment-related surgical delay or serious adverse events reported. Treatment-related adverse events occurred in 86.7% of patients, with the most commonly reported being decreased white blood cell count, constipation, decreased neutrophil count, nausea, and rash. Grades 3 treatment-related adverse events occurred in 20.0% of patients.<br /><br />In terms of efficacy, the study found that 96.4% of patients who underwent surgical resection achieved successful R0 resection. A major pathologic response was observed in 7.1% of patients, while no pathologic complete response was observed. Radiological assessment showed an objective response rate of 82.8% and a disease control rate of 96.6%.<br /><br />Overall, neoadjuvant icotinib plus chemotherapy demonstrated clinically meaningful efficacy in patients with resectable, stage II-IIIB EGFRm NSCLC. The treatment was well tolerated, and there were no unexpected safety signals. The study is ongoing, and updated results will be presented at a later date.

Asset Subtitle

Fang-Liang Lu

Meta Tag

Speaker Fang-Liang Lu

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

neoadjuvant

icotinib

chemotherapy

safety

efficacy

resectable

stage II-IIIB

EGFR-mutant

non-small cell lung cancer

NSCLC